Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | CTSK | P43235 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17553141 | 0.91 | PPARG (0.57) | PPARGPPARACACNA1BITGB3ITGA2B | |
| SCHEMBL5408855 | 0.91 | PPARG (0.57) | PPARGPPARACACNA1BITGB3ITGA2B | |
| SCHEMBL13402356 | 0.91 | PPARG (0.57) | PPARGPPARACACNA1BITGB3ITGA2B | |
| SCHEMBL5408845 | 0.91 | PPARG (0.57) | PPARGPPARACACNA1BITGB3ITGA2B | |
| SCHEMBL8366868 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BCTSSCTSKCYP1A2 | |
| SCHEMBL27700285 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BCTSSCTSKCYP1A2 | |
| SCHEMBL8366834 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BCTSSCTSKCYP1A2 | |
| SCHEMBL20045974 | 0.88 | PPARG (0.53) | PPARGPPARAITGB3ITGA2BCTSS | |
| SCHEMBL14803767 | 0.88 | PPARG (0.53) | PPARGPPARAITGB3ITGA2BCTSS | |
| SCHEMBL7260689 | 0.87 | CTSS (0.63) | ITGB3ITGA2BCTSSCTSKCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022167087-A1 | PEPTIDASE ENHANCED CYTOTOXIC DIPEPTIDES | ONCOPEPTIDES AB (SE) | 2022-08-11 | — | — | WO | disclosed |
| EP-1290011-B1 | MELPHALAN DERIVATIVES AND THEIR USE AS CANCER CHEMOTHERAPEUTIC DRUGS | ONCOPEPTIDES AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-6992207-B2 | Melphalan derivatives and their use as cancer chemotherapeutic drugs | ONCOPEPTIDES AB (SE) | 2006-01-31 | — | — | US | disclosed |
| US-20040097421-A1 | Melphalan derivatives and their use as cancer chemotherapeutic drugs | ONCOPEPTIDES INNOVATION AB (SE) | 2004-05-20 | — | — | US | disclosed |
| EP-1290011-A1 | MELPHALAN DERIVATIVES AND THEIR USE AS CANCER CHEMOTHERAPEUTIC DRUGS | Oncopeptides AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096367-A1 | MELPHALAN DERIVATIVES AND THEIR USE AS CANCER CHEMOTHERAPEUTIC DRUGS | ONCOPEPTIDES AB (SE) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097421-A1 | Melphalan derivatives and their use as cancer chemotherapeutic drugs | MCL1, LNPEP, MYADM | PPARG 4666/4885PPARA 3389/4885CACNA1B 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.